In Bruin CLL-322, relapsed patients receiving standard venetoclax-rituximab had a median progression-free survival of roughly 39 months, significantly shorter than the 54 months observed in the Murano trial. Because patients spend 24 months on therapy, 15 months off treatment may limit future venetoclax retreatment durability.
While pivotal trial data for liso-cel showed a modest 20% complete response rate, real-world studies demonstrate complete response rates reaching 40% to 50%. Dr. Koons notes that heavily pretreated patients lacking effective bridging agents often presented with bulky disease, which pirtobrutinib bridging helps control prior to CAR-T.
Recent guidelines position CAR-T ahead of allogeneic stem cell transplantation for patients who have failed covalent BTK inhibitors and venetoclax. Dr. Koons emphasizes that CAR-T carries a superior safety profile by avoiding graft-versus-host disease, allowing clinicians to reserve allogeneic transplant for CAR-T failures or clonally related Richter's transformation.
Using the bispecific antibody epcoritamab directly in CLL patients with active disease triggers severe cytokine release syndrome due to high circulating disease burden. Administering fixed-duration venetoclax beforehand debulks tumor load, resulting in significantly lower cytokine release syndrome rates while achieving high undetectable minimal residual disease responses.
Most diffuse large B-cell lymphomas arising in CLL patients are clonally related, driving poor outcomes with standard R-CHOP chemotherapy. However, Dr. Koons notes that clonally unrelated cases behave similarly to de novo DLBCL and achieve favorable remissions with R-CHOP alone, whereas clonally related or TP53-mutated cases require novel agent regimens.
Although investigational BTK degraders demonstrate 22 to 24 months of median progression-free survival in refractory CLL, continuous frontline application risks selecting for the A428D mutation. This recurrent mutation renders CLL cells resistant to all BTK-targeting agents, prompting caution against continuous frontline use over time-limited combinations.
